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Derived from phase I data, Japanese early phase II studies of S-1 adopted a fi xed dose of 75 mg twice a day. However, skin rash and diarrhea hindered further conduct of the trial, and the dose was reduced to 50 mg twice a day. In consideration of the safety profi les of the fi xed-dose schedule, the dose of the late phase II trials was modifi ed to 80 mg/m 2 according to the body surface area (BSA). The applied dose ranged from 64 mg/m 2 to 80 mg/m 2 with a graded system; 80 mg for BSA less than 1.25 m . This BSA-based dosing system differed from the Western dosing system in that it fi xed the dosage for patients with a BSA greater than 1.5 m 2 . As a result, in patients with a BSA of more than 1.5 m 2 , the actual administered dose is not 80 mg/m 2 and there is a risk of underdosing. However, the safety profi le using this system is better than with a fi xed dosing schedule, and S-1 with this dosing system has been the preferred oral agent for the treatment of gastric cancer in Japan.
Based on the Japanese response evaluation criteria, which include primary gastric cancer as a measurable lesion, S-1 demonstrated excellent activity in patients with advanced gastric cancer, with a response rate of 45%-54% in early phase II Japanese trials [2] [3] [4] . In these trials, even though the incidence of overall toxicity was as high as 83%, the toxicity profi le was mild, with a less than 10% incidence of grade III or IV toxicities. And in a post-marketing survey, the incidence of toxicity was 74.1% with the 80 mg/m 2 Japanese dosing system with 4-week treatment and a 2-week rest schedule. This incidence of general toxicity was almost equal to that in the pre-marketing clinical trials. The major reasons for discontinuation of S-1 during the fi rst or second cycle of the treatment were disease symptom progression (43%) or toxicities (33%). The adverse reactions during each cycle appeared mainly during the 2-3 weeks after Introduction S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fl uoropyrimidine (DIF) developed from the biochemical modulation of 5-fl uorouracil (5-FU). S-1 is a triple compound consisting of tegafur (FT), gimestat (CDHP), and otastat potassium (Oxo) at molar ratios of 1 : 0.4 : 1, respectively. S-1 bioavailability was improved by the addition of gimestat, which has DPD-the start of treatment [5] . In contrast, the toxicity pattern of S-1 is completely different outside Japan. In a phase I trial conducted in the United States, the clinically recommended dose was 60 mg/m 2 a day, because of diarrhea and hyperbilirubinemia. [6] . In one European phase II study, diarrhea caused an immediate dose reduction, from 80 mg/m 2 to 70 mg/m 2 after the enrollment of only a few patients [7] . In a phase II trial conducted in Korea, which was the fi rst Asian trial outside Japan, the tolerability was really good. In this trial, the initial dose of 70 mg/m 2 was increased to 80 mg/m 2 because there was no incidence of any grade III or IV toxicity at the 70 mg/m 2 dosage. Moreover, in this trial, there was no grade IV toxicity and the major adverse event was anemia [8] . These fi ndings suggest that there may be ethnic differences in the toxicity profi les of S-1 treatment. With the microarray comparative genomic hybridization (CGH) technique, 18 genes have been identifi ed with copy number changes associated with the hemoglobin reduction in response to S-1 treatment [8] .
Ethnic differences in S-1 adverse events
There have been fi ve phase I trials of S-1 monotherapy reported since 2000: one from Europe and four from the United States, each with different treatment schedules [9] [10] [11] [12] . With two doses scheduled per day, the maximum tolerable dose (MTD) ranged between 70 and 90 mg/ m 2 , depending on the treatment duration per cycle (2 weeks-4 weeks). With the single-dose treatment, the MTD was 60 mg/m 2 , regardless of the treatment duration (3 weeks-4 weeks). The most common doselimiting toxicity (DLT) in Caucasians was diarrhea, regardless of the treatment schedule, duration, or dosage (Table 1) . During the 2-week treatment and 1-week rest cycle, there were no grade IV toxicities, even with diarrhea as the DLT [12] .
There have been fi ve phase II trials of S-1 monotherapy since 1998: three from Japan, one from Europe, and one from Korea [2-4, 7, 8] . All the trials involved a schedule of two doses per day, with 4-week treatment duration in each cycle and a 1-week rest period in Europe and a 2-week rest period in Asia. The major toxicities in Asian patients were anemia and granulocytopenia, whereas diarrhea was the most common toxicity in European patients (Table 2) .
When we compared the toxicities among Korean (70 mg/m and 80 mg/m 2 ), Japanese and European (70 mg/m 2 and 80 mg/m 2 ) patients, the incidence of grade I-II anemia was similar for European and Korean patients. But grade III-IV anemia was highest in Korean patients. The incidence of grade I-II leukopenia was similar in patients from Korea, Japan, and Europe. But the incidence of grade IV leukopenia was relatively low , there was no difference in grade III-IV diarrhea between Korean and European patients, but at the 70 mg/m 2 dose, diarrhea was slightly more common in European patients compared to Korean and Japanese patients (Table 3) .
In a small Japanese retrospective study comparing a 4-2-week schedule (4-week treatment and 2-week rest) and a 2-1-week schedule (2-week treatment and 1-week rest), the incidence of overall toxicity was lower for the 2-1-week schedule (77% versus 93%), while the response rates were similar in the two schedules (23% versus 21%) [13] . Anemia was the major toxicity in a phase II trial conducted with the 2-1-week schedule in Korean patients who had a poor performance status [14] . As this trial was performed in patients with a poor performance status, grade III-IV toxicities (except for anemia) were more common than those seen in a previous trial in Korean patients treated with the 4-2-week schedule (Table 4) .
Potential ethnic differences in S-1 tolerance and toxicity may be explained by ethnic differences in S-1 metabolism. Myelosuppression was the main DLT that precluded dose escalation in Japan, while gastrointestinal and skin toxicities were the major DLTs in Caucasians. A pharmacokinetic (PK) profi le study of 5-FU, tegafur, CDHP, and Oxo was performed during cycles 1 and 3 in Korean patients [8] . The PK profi le showed dose dependency for the 70 mg/m 2 to 80 mg/m 2 doses. But the AUC of 5-FU increased only marginally, suggesting that the conversion of FT to 5-FU was saturated at the 80 mg/m 2 dosage. This conversion level was similar to that seen in the Japanese population [15] . As the Japanese 80 mg/m 2 dose is equivalent to the Korean 70 mg/m 2 dose with dose rounding, the PK profi le for Japanese at the 80 mg/m 2 dose was quite similar to the Korean PK profi le at the 70 mg/m 2 dose. The only difference was a trend for a higher blood Oxo level in Anemia  36  26  30  19  88  95  87  68  Leukopenia  54  38  44  23  45  34  13  36  Thrombocytopenia  7  30  6  7  14  26  3  3  Mucositis  11  24  12  12  26  5  16  29  Diarrhea  11  10  6  14  24  13  26  26  Anorexia  18  10  -20  10  13  71  47  Hyperbilirubinemia  ---12  --10 Japanese patients compared to Korean patients, which may have resulted from less absorption of Oxo from the intestine. Further studies using mucosal biopsy and measurement of the Oxo level in the intestinal mucosa could prove the hypothesis of ethnic differences in the intestinal absorption of Oxo. It is not surprising that that Korean PK profi les for S-1 and its components were more similar to those of the Japanese rather than Caucasians; however, this PK study [8] did not explain the discrepancy in adverse events observed between Korean and Japanese patients, thus warranting a pharmacogenomic study using genomic DNA.
Pharmacogenomic study using cDNA microarray CGH
Conventional comparative genomic hybridization (CGH) technology was developed to screen for chromosomal alterations on a genome-wide scale. However, the resolution range with conventional CGH is only 3-10 Mb [16] . Microarray technology allows for the simultaneous measurement of a large number of genes at the single-gene level. Array-based CGH combines microarray technology with conventional CGH to identify a large quantity of genetic alterations at the wholechromosome level [16, 17] . Array-CGH technology is classifi ed into three types based on the types of probes used: bacterial artifi cial chromosome (BAC), phage artifi cial chromosome (PAC), and cDNA or oligonucleotide array CGH. Initially, BAC array CGH consisted of 2400 clones covering the whole genome, and thus the resolution was approximately 1.0 Mb [18] . As a result of continuous technical development, the BAC array at present has been expanded to include 30 000 clones for wider coverage of the whole genome [19] . However, BAC array CGH still has problems in terms of experimental time, cost, and resolution limitation. Microarray CGH using cDNA or oligonucleotides can increase the resolution level to the single gene [17, 20] . In microarray CGH, the genomic DNA from a patient is compared to reference genomic DNA (from placenta) with different color makers (Fig. 1) . A pharmacogenomic study can be done using both genomic DNA from peripheral blood mononuclear cells and tumor DNA from cancer. While somewhat controversial, the genomic DNA is considered to represent the genetic information from the normal tissue, not from the tumor tissue [21] . Generally, the normal tissue is used for toxicity assay and the tumor tissue is used for tumor response assay.
It is well known that most anticancer agents directly suppress hematopoietic stem cells or indirectly suppress the microenvironment of the bone marrow. However, without evidence of bleeding, it is not common that anemia alone, without any leucopenia or thrombocytopenia, is the unique chemotherapy-induced bone marrow suppression phenotype. There have been several reports about 5-FU and uracil-tegafur (UFT)-associated hemolytic anemia [22] . In these patients, drug-induced hemolytic anemia was usually associated with long-term exposure, with accompanying clinical symptoms such as dark-colored urine, jaundice, and hepatosplenomegaly, and abnormal laboratory fi ndings. In both Korean and Caucasian patients, several patients have presented with hyperbilirubinemia, but these patients did not show any anemia [6] . The pathophysiology of hyperbilirubinemia after S-1 treatment is unknown. One possible explanation is the saturation of glucuronyltransferase enzymatic activity or the hepatobiliary transportation of S-1, which has no direct correlation with anemia [23, 24] .
S-1 treatment-related anemia appears early during the treatment period. Thirteen percent of the patients had grade III anemia at least once during the treatment course, and 42% of the patients experienced grade II-III anemia during the fi rst cycle. The overall incidence of anemia in all patients was relatively constant throughout the treatment cycles [8] . In Korean patients with colorectal cancer, the most common hematologic adverse event was anemia without evidence of bleeding, which occurred in 50% of the patients. And in these patients, the S-1 treatment schedule was 2-week treatment with a 1-week rest cycle [25] . When the PK profi les were similar in Korean, Japanese, and Caucasian patients and there was no defi nite evidence of bleeding or hemolysis, there was some evidence of genetic involvement in the S-1 treatment-induced anemia; the anemia occurred continuously after treatment and resolved with the cessation of S-1 treatment, there was interpatient variability in the rapidity of anemia occurrence in each cycle, and gradual macrocytosis occurred with S-1 treatment, possibly refl ecting deranged DNA synthesis and mitosis. Because there were no known genes correlated with either anemia or S-1 treatmentinduced anemia, we utilized a pharmacogenomic approach to compare the whole genomes of patients with hemoglobin reduction and patients without such reduction after S-1 treatment. As the mean hemoglobin reduction per cycle was 1.0, microarray based CGH was done comparing two groups of patients: patients with mild hemoglobin reduction (MRG; less than 1.0 per cycle) versus those with severe hemoglobin reduction (SRG; more than 1.0 per cycle). The hemoglobin reduction velocity was defi ned as the slope, which is the difference between the hemoglobin levels (Hb initial -Hb nadir ) divided by the number of S-1 cycles during which the initial anemia occurred. The microarray CGH was done in a sex-matched design [26] . The signal intensity of each spot was transformed as the log 2 red-to-green (R/G) ratio. Whole microarray spots were mapped on each chromosomal location using SOURCE (http://genome-www5.stanford.edu/cgi-bin/source/ sourceSearch) and DAVID (http://apps1.niaid.nih.gov/ david/). Genes were selected with two different criteria, which is a different way of mRNA expression profi ling. First, genes with copy number variations defi ned as an amplifi cation [log 2 (R/G) > 0.68] or a deletion [log 2 (R/G) < −0.68] were selected (Fig. 2) . Second, genes varying in copy number in more than 30% of the patients were selected [27, 28] . Theoretically, the log 2 ratio with a single copy change of each gene in microarray CGH is supposed to be 1.0. But the experimental value for genes with a single copy change showed wide variation. For the sex chromosomes, a log 2 ratio of 0.22-0.28 was suggested for a single copy change [29, 30] . With an indirect study design, ranges of 0.2-0.6 had been suggested for a single copy change [31, 32] and a log 2 ratio of 0.68 was suggested as the criterion for genome alterations, such as duplicated or deleted gene changes, regardless of differences in microarray study design (direct, indirect, sex-matched, sex-mismatched; Fig. 3 ) [28] . The selected genes were then mapped on each chromosome (Fig. 4) . When genes with copy number variation are selected, univariate analysis can be performed using clinical factors and selected genes to defi ne the factors associated with hemoglobin reduction. Then a logistic regression model can be built for predicting hemoglobin reduction, using the selected factors or genes (Fig. 5) . The initial hemoglobin level and three selected genes were reported with 92% prediction accuracy using the fi nal regression model with an AUC of 0.98 [8] . Among the selected genes, Grb7 was reported to participate in the maturation of erythroid cells, and the estrogen receptor beta gene was associated with the differentiation of pluripotent hematopoietic cells [33, 34] .
There have been some controversial reports that describe a correlation between toxicity and patient survival. Breast cancer patients with hematologic toxicity have longer survival than patients without toxicity. Patients with non-small-cell lung cancer with neutropenia also have longer survival than those without neutropenia. In contrast, gastric cancer patients with moderate neutropenia have longer survival than patients with mild or severe neutropenia. However, there may be false associations in these data; for example, patients with poor survival may have shorter treatment periods and show less toxicity, whereas patients with longer survival may have longer treatment periods and show more toxicity. For a predictive study, this kind of clinical bias must be controlled for in the study design.
Future directions
For the validation of the genes selected, more studies are required, such as: (1) a prospective comparison in clinically matched patients with and without anemia, (2) validation of the selected genes from independent patients, and (3) an exclusion study of drug metabolism-related genes, such as the cytochrome p450 family (CYP 2A6) or the DPD gene, in patients with anemia. The utility of pharmacogenomic approaches to explain the ethnic variability in S-1-induced toxicity remains speculative and can be optimized through prospective validation. 
